Key Q Fever Market Players:
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline (GSK)
- Sanofi S.A.
- Bavarian Nordic A/S
- Takeda Pharmaceutical Company
- CSL Limited
- SK Bioscience Co., Ltd.
- Serum Institute of India
- Biocon Limited
- Hualan Biological Engineering
- Novavax, Inc.
- Mitsubishi Tanabe Pharma
- Seqirus (CSL Subsidiary)
- Janssen Pharmaceuticals
- LG Chem Life Sciences
- Panacea Biotec Ltd.
- Valeant Pharmaceuticals
- BioCSL (CSL Limited Subsidiary)
- Fujifilm Toyama Chemical Co., Ltd.
- Incepta Pharmaceuticals Ltd.
The Q fever market globally has several multinational companies. These companies focus on developing comprehensive partnerships with governing bodies and health agencies. Further, advancing vaccine technology in terms of recombinant and next-generation vaccine platforms is key. Expansion in terms of clinical trial work, securing regulatory approvals, and growth in product manufacturing scale serve to solidify growth strategies.
Top 20 Global Manufacturers in the Q Fever Market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In 2025, the industry size of Q fever is evaluated at USD 985 million.
Q Fever Market size was valued at USD 943 million in 2024 and is projected to reach USD 5.50 billion by the end of 2034, rising at a CAGR of 4.6% during the forecast period, i.e., 2025-2034.
The North America industry is expected to dominate the global market with a share of 36% by the end of 2034.
The major players in the market are Pfizer Inc., Arix Bioscience plc, Yashica Pharmaceuticals Pvt. Ltd, Merck KGaA, Melinta Therapeutics LLC, Teva Pharmaceutical Ltd., Bayer AG, and Johnson & Johnson Services, Inc.
